{
  "nodes": [
    {
      "id": "node_001",
      "content": "EGFR exon 20 insertion mutation",
      "parent_ids": [],
      "children_ids": [
        "node_002",
        "node_003"
      ],
      "tree_ids": [],
      "footnote_labels": [
        "nn"
      ]
    },
    {
      "id": "node_002",
      "content": "Amivantamab-vmjw + carboplatin/pemetrexed (nonsquamous) (category 1) (preferred)",
      "parent_ids": [
        "node_001"
      ],
      "children_ids": [
        "node_004"
      ],
      "tree_ids": [],
      "footnote_labels": [
        "rr"
      ]
    },
    {
      "id": "node_003",
      "content": "Systemic Therapy, Adenocarcinoma (NSCL-K 1 of 5) or Squamous Cell Carcinoma (NSCL-K 2 of 5)",
      "parent_ids": [
        "node_001"
      ],
      "children_ids": [
        "node_006"
      ],
      "tree_ids": [
        "NSCL-K 1 of 5",
        "NSCL-K 2 of 5"
      ],
      "footnote_labels": []
    },
    {
      "id": "node_004",
      "content": "Progression",
      "parent_ids": [
        "node_002"
      ],
      "children_ids": [
        "node_005"
      ],
      "tree_ids": [],
      "footnote_labels": []
    },
    {
      "id": "node_005",
      "content": "Systemic Therapy, Subsequent (NSCL-K 4 of 5)",
      "parent_ids": [
        "node_004"
      ],
      "children_ids": [],
      "tree_ids": [
        "NSCL-K 4 of 5"
      ],
      "footnote_labels": [
        "kkk"
      ]
    },
    {
      "id": "node_006",
      "content": "Tumor response evaluation",
      "parent_ids": [
        "node_003"
      ],
      "children_ids": [
        "node_007",
        "node_008"
      ],
      "tree_ids": [],
      "footnote_labels": []
    },
    {
      "id": "node_007",
      "content": "Progression",
      "parent_ids": [
        "node_006"
      ],
      "children_ids": [
        "node_014"
      ],
      "tree_ids": [],
      "footnote_labels": []
    },
    {
      "id": "node_008",
      "content": "Response or stable disease",
      "parent_ids": [
        "node_006"
      ],
      "children_ids": [
        "node_009"
      ],
      "tree_ids": [],
      "footnote_labels": []
    },
    {
      "id": "node_009",
      "content": "4–6 cycles (total)",
      "parent_ids": [
        "node_008"
      ],
      "children_ids": [
        "node_010"
      ],
      "tree_ids": [],
      "footnote_labels": [
        "jjj"
      ]
    },
    {
      "id": "node_010",
      "content": "Tumor response evaluation",
      "parent_ids": [
        "node_009"
      ],
      "children_ids": [
        "node_011",
        "node_012"
      ],
      "tree_ids": [],
      "footnote_labels": []
    },
    {
      "id": "node_011",
      "content": "Progression",
      "parent_ids": [
        "node_010"
      ],
      "children_ids": [
        "node_014"
      ],
      "tree_ids": [],
      "footnote_labels": []
    },
    {
      "id": "node_012",
      "content": "Response or stable disease",
      "parent_ids": [
        "node_010"
      ],
      "children_ids": [
        "node_013"
      ],
      "tree_ids": [],
      "footnote_labels": []
    },
    {
      "id": "node_013",
      "content": "Maintenance Therapy (NSCL-K 3 of 5)",
      "parent_ids": [
        "node_012"
      ],
      "children_ids": [
        "node_016"
      ],
      "tree_ids": [
        "NSCL-K 3 of 5"
      ],
      "footnote_labels": []
    },
    {
      "id": "node_014",
      "content": "Amivantamab-vmjw",
      "parent_ids": [
        "node_007",
        "node_011",
        "node_016"
      ],
      "children_ids": [
        "node_015"
      ],
      "tree_ids": [],
      "footnote_labels": []
    },
    {
      "id": "node_015",
      "content": "Systemic Therapy, Subsequent (NSCL-K 4 of 5)",
      "parent_ids": [
        "node_014"
      ],
      "children_ids": [],
      "tree_ids": [
        "NSCL-K 4 of 5"
      ],
      "footnote_labels": [
        "kkk"
      ]
    },
    {
      "id": "node_016",
      "content": "Progression",
      "parent_ids": [
        "node_013"
      ],
      "children_ids": [
        "node_014"
      ],
      "tree_ids": [],
      "footnote_labels": []
    }
  ],
  "tree_references": [
    {
      "from_tree": "NSCL-25",
      "to_tree": "NSCL-K 1 of 5",
      "description": "Systemic Therapy, Adenocarcinoma"
    },
    {
      "from_tree": "NSCL-25",
      "to_tree": "NSCL-K 2 of 5",
      "description": "Systemic Therapy, Squamous Cell Carcinoma"
    },
    {
      "from_tree": "NSCL-25",
      "to_tree": "NSCL-K 4 of 5",
      "description": "Systemic Therapy, Subsequent"
    },
    {
      "from_tree": "NSCL-25",
      "to_tree": "NSCL-K 3 of 5",
      "description": "Maintenance Therapy"
    },
    {
      "from_tree": "NSCL-25",
      "to_tree": "NSCL-H",
      "description": "Principles of Molecular and Biomarker Analysis (Footnote nn)"
    },
    {
      "from_tree": "NSCL-25",
      "to_tree": "NSCL-J",
      "description": "Molecular or Biomarker-Directed Therapy for Advanced or Metastatic Disease (Footnote rr)"
    }
  ],
  "footnotes": [
    {
      "label": "nn",
      "content": "Principles of Molecular and Biomarker Analysis (NSCL-H)."
    },
    {
      "label": "rr",
      "content": "Molecular or Biomarker-Directed Therapy for Advanced or Metastatic Disease (NSCL-J)."
    },
    {
      "label": "iii",
      "content": "Monitoring During Initial Therapy: Response assessment after 2 cycles, then every 2–4 cycles with CT of known or high-risk sites of disease (eg, chest, abdomen, pelvis) with or without contrast or when clinically indicated. Timing of CT scans within Guidelines parameters is a clinical decision."
    },
    {
      "label": "jjj",
      "content": "In general, 4 cycles of initial systemic therapy (ie, with carboplatin or cisplatin) are administered prior to maintenance therapy. However, if patient is tolerating therapy well, consideration can be given to continue to 6 cycles."
    },
    {
      "label": "kkk",
      "content": "Monitoring During Subsequent Therapy or Maintenance Therapy: Response assessment with CT of known or high-risk sites of disease (eg, chest, abdomen, pelvis) with or without contrast every 6–12 weeks. Timing of CT scans within Guidelines parameters is a clinical decision."
    }
  ],
  "extraction_confidence": 0.95,
  "image_title": "EGFR EXON 20 INSERTION MUTATION",
  "tree_id": "NSCL-25",
  "keywords": [
    "KRAS",
    "sotorasib",
    "adagrasib"
  ]
}
